Syra Health Corp. (SYRA) proposes a primary offering of 3,203,125 Class A common shares with accompanying Series A and Series B warrants, plus up to 6,566,406 Class A shares issuable upon exercise of the Series A, Series B and placement agent warrants. Each offered share is bundled with one warrant of each investor series at a combined public offering price of $0.64. The securities may not be sold until the registration statement is effective; there is no minimum amount required to close, and the placement agent is to use reasonable best efforts.
Syra estimates net proceeds of approximately $1.6 million, assuming no exercise of the warrants, for marketing and sales, application development, research and development, and general corporate purposes. Revenue was approximately $7.2 million in 2025 versus $8.0 million in 2024; net loss was $896,333 in 2025 versus $3,759,238 in 2024, while net income was $491,221 for the six months ended June 30, 2026. Cash was $2,123,747 as of June 30, 2026. The auditor expressed substantial doubt about Syra’s ability to continue as a going concern, and Syra expects existing cash and cash from operations will not fund current operations through at least 12 months from the prospectus date.
Syra Health Corp CEO Gregory R. Alexander was granted 368,458 performance stock units on August 31, 2026. His reported post-grant position was 368,458 units, tied to 368,458 underlying Class A Common Stock shares. The award provides that 20% of the units vest one year after the grant date; the remainder vest upon achievement of certain company financial metrics.
Syra Health Corp reported that its CEO, Gregory R. Alexander, received grants of 257,920 stock options and 110,537 restricted stock units on January 5, 2026. Twenty percent of each award vests on each December 31 from 2026 through 2030. The options have a $0.09 per-share exercise price and expire January 5, 2036.
Syra Health Corp COO and CFO Priya Prasad received compensation-related awards on August 31, 2026: 86,696 Performance Stock Units, 60,687 stock options, and 26,009 Restricted Stock Units. Those amounts are her reported post-transaction positions in each award. The options have an exercise price of $0.92 per share.
Twenty percent of the Performance Stock Units vest each year after the grant, subject to achievement of certain company financial metrics. Twenty percent of the options and restricted stock units vest on each December 31 from 2026 through 2030.
Syra Health Corp (SYRA) has filed a Form S-1 registering for resale up to 3,171,100 shares of Class A common stock issuable upon exercise of its Series B warrants. The warrants, issued in a September 2024 registered direct offering, are exercisable at $0.64 per share until September 13, 2029. Syra will not receive proceeds from selling stockholders’ resales but would receive up to about $2.03 million in gross cash proceeds if all such warrants are exercised for cash.
Syra is a healthcare services company focused on behavioral and mental health (including its Syrenity app launched in late 2024), population health analytics, digital health platforms, health education, and healthcare workforce staffing. Revenue was $8.0 million in 2024, $7.2 million in 2025, and $4.7 million for the six months ended June 30, 2026.
The company reported net losses of $3.76 million in 2024 and $0.90 million in 2025, but net income of $0.49 million for the first half of 2026, with an accumulated deficit of $9.23 million and cash of $2.12 million as of June 30, 2026. Its auditor raised substantial doubt about its ability to continue as a going concern, and management expects existing cash and cash from operations will not fund operations for 12 months without additional capital. Syra is an emerging growth and smaller reporting company, trades on the OTCQB, and highlights significant customer concentration and extensive healthcare regulatory and government contracting risks.
Syra Health Corp (SYRA) reported that its COO and CFO, Priya Prasad, received equity awards on August 31, 2026. These include 86,696 Performance Stock Units tied to company financial metrics, 60,687 stock options with a $0.92 exercise price, and 26,009 Restricted Stock Units, all relating to Class A common stock.
Twenty percent of the Performance Stock Units vest each year after the grant date subject to achieving specified company financial metrics. Twenty percent of the options and Restricted Stock Units vest on each of December 31, 2027, 2028, 2029, 2030 and 2031; the options and Performance Stock Units expire on August 31, 2036. No Rule 10b5-1 trading plan is reported.
Syra Health Corp reported that CEO Alexander Gregory R. received a grant of 368,458 Performance Stock Units linked to Class A Common Stock. The units carry a zero exercise price and expire on August 11, 2036. According to the vesting terms, 20% of the Performance Stock Units vest one year after the grant date, with the remaining units vesting upon achievement of specified company financial metrics, tying a substantial portion of this award to the company’s future performance.
Syra Health Corp. reported improved results for the three and six months ended June 30, 2026. Net revenues were $4,667,943 for the six months, up from $3,803,973, driven by growth in population health and healthcare workforce services. For the same period, net income was $491,221 versus a net loss of $535,861 in 2025, reflecting higher gross profit and lower operating expenses. Cash and cash equivalents were $2,123,747 and working capital was $2,551,002 as of June 30, 2026, with net cash provided by operating activities of $643,183.
Despite these gains, management states that there is substantial doubt about the company’s ability to continue as a going concern over the next twelve months without additional capital, citing early-stage operations and limited visibility on revenues. The company also highlights significant customer concentration and dependence on government-related contracts. Subsequent to quarter-end, Syra obtained contract extensions with several customers and disclosed an anticipated CMS ACCESS Model partnership that it expects to be a durable revenue source over ten years.